4/A: Zenas BioPharma CEO Reports Conversion of Preferred Stock and Stock Option Grant Following IPO

Leon O. Moulder, Jr., CEO of Zenas BioPharma, files an amended Form 4 detailing the conversion of preferred stock to common stock and a new stock option grant following the company's initial public offering.

Summary

• Leon O. Moulder, Jr., the CEO of Zenas BioPharma, filed an amended Form 4 with the SEC.
• The filing reports changes in beneficial ownership of securities due to the automatic conversion of Series Seed, Series A, and Series B convertible preferred stock into common stock upon the closing of Zenas BioPharma's initial public offering (IPO) on September 16, 2024.
• The conversion ratio was 8.6831-for-1 for all series of preferred stock.
• The filing also reports the grant of a stock option to purchase 1,486,000 shares of common stock on September 12, 2024, with an exercise price of $17.
• The option vests over 4 years, with 25% vesting on September 12, 2025, and the remainder vesting monthly over the following 36 months, contingent upon continued service.
• The amendment corrects previously reported amounts of securities beneficially owned following reported transactions.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing detailing expected changes following an IPO. The stock option grant is a positive sign of alignment between management and shareholders.

Positives

• The conversion of preferred stock to common stock simplifies the company's capital structure following the IPO.
• The stock option grant incentivizes the CEO to drive long-term value creation for shareholders.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Management Comments

• Leon O. Moulder, Jr. disclaims beneficial ownership of shares held by Tellus BioVentures LLC except to the extent of his pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, particularly after significant events like an IPO. The conversion of preferred stock to common stock is a typical step in simplifying the capital structure post-IPO.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biopharmaceutical industry.
• Vesting schedules of 4 years with a one-year cliff are also typical.
• Comparing the size of the option grant to those of CEOs at comparable companies (e.g., similar market capitalization and stage of development) would provide further context on its relative value.

Stakeholder Impact

• Shareholders will see a simplified capital structure with the conversion of preferred stock to common stock.
• The stock option grant aligns the CEO's interests with those of shareholders, incentivizing long-term value creation.

Key Dates